Andrew Obenshain net worth and biography

Andrew Obenshain Biography and Net Worth

Insider of bluebird bio

Andrew Obenshain has served as head of Europe since 2016. He was most recently at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, Andrew spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations. Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his B.A. in genetics, cell and developmental biology from Dartmouth College.

What is Andrew Obenshain's net worth?: The estimated net worth of Andrew Obenshain is at least $73,570.30 as of February 3rd, 2025. Mr. Obenshain owns 18,485 shares of bluebird bio stock worth more than $73,570 as of March 6th. This net worth estimate does not reflect any other assets that Mr. Obenshain may own. Additionally, Mr. Obenshain receives an annual salary of $1,040,000.00 as Insider at bluebird bio. Learn More about Andrew Obenshain's net worth.
How old is Andrew Obenshain?: Mr. Obenshain is currently 50 years old. There are 3 older executives and no younger executives at bluebird bio. Learn More on Andrew Obenshain's age.
What is Andrew Obenshain's salary?: As the Insider of bluebird bio, Inc., Mr. Obenshain earns $1,040,000.00 per year. Learn More on Andrew Obenshain's salary.
How do I contact Andrew Obenshain?: The corporate mailing address for Mr. Obenshain and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at investor@bluebirdbio.com. Learn More on Andrew Obenshain's contact information.
Has Andrew Obenshain been buying or selling shares of bluebird bio?: During the last ninety days, Andrew Obenshain has sold $1,929.14 in shares of bluebird bio stock. Most recently, Andrew Obenshain sold 86 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.39, for a transaction totalling $635.54. Following the completion of the sale, the chief executive officer now directly owns 18,485 shares of the company's stock, valued at $136,604.15. Learn More on Andrew Obenshain's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 396 shares worth more than $3,233.92. The most recent insider tranaction occured on February, 3rd when insider Thomas J Klima sold 122 shares worth more than $901.58. Insiders at bluebird bio own 1.4% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 2/3/2025.

Andrew Obenshain Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/3/2025	Sell	86	$7.39	$635.54	18,485
1/6/2025	Sell	140	$9.24	$1,293.60	18,571
12/10/2024	Sell	48	$8.40	$403.20	18,712
2/5/2024	Sell	93	$18.00	$1,674.00	14,304
1/5/2024	Sell	158	$28.60	$4,518.80	14,398
8/10/2023	Sell	846	$70.80	$59,896.80	14,597
1/11/2023	Sell	158	$156.00	$24,648.00	12,134
11/4/2022	Sell	63	$128.20	$8,076.60	12,293
8/4/2022	Sell	1,090	$87.80	$95,702.00	12,356
1/10/2022	Sell	152	$187.20	$28,454.40
12/7/2021	Sell	41	$203.60	$8,347.60
6/4/2021	Sell	25	$615.00	$15,375.00	1,979
5/3/2021	Sell	1	$603.00	$603.00	2,005

Andrew Obenshain Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $4.11

$3.86

$4.13

50 Day Range

MA: $7.11

$3.80

$9.92

2 Week Range

Now: $4.11

$3.56

$33.20

Volume

213,911 shs

Average Volume

368,324 shs

Market Capitalization

$39.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Andrew Obenshain Biography and Net Worth

What is Andrew Obenshain's net worth?

How old is Andrew Obenshain?

What is Andrew Obenshain's salary?

How do I contact Andrew Obenshain?

Has Andrew Obenshain been buying or selling shares of bluebird bio?

Who are bluebird bio's active insiders?

Are insiders buying or selling shares of bluebird bio?